恩帕格利弗洛辛对心力衰竭患者的外周微血管功能障碍的影响,心力衰竭患者的心脏衰竭患者的心脏衰竭患者的心脏衰竭患者的心脏衰竭患者的心脏衰竭患者的心脏衰竭患者的心脏衰竭患者的心脏衰竭患者的心脏衰竭患者的心脏衰竭患者的心脏衰竭患者的心脏衰竭患
Sanne G J Mourmans1, Anouk Achten1, Raquel Hermans1
1Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands.
Cardiovascular diabetology
|April 25, 2025
概括
恩帕格利弗洛辛治疗通过增强胰岛素介导血液流动,改善了心力衰竭与保存喷射小部分 (HFpEF) 患者的外周微血管功能. 这表明HFpEF中的微血管功能障碍是可修改的,这需要进一步的临床研究.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 血管生物学 血管生物学
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭与全身微血管功能障碍有关.
- 作为一种有效的HFpEF治疗方法的empagliflozin的确切机制尚不清楚.
- 这项研究调查了empagliflozin在HFpEF中对外周微血管功能的影响.
研究的目的:
- 评估empagliflozin对HFpEF患者外周微血管功能的影响.
- 在HFpEF中探索empagliflozin治疗作用的潜在机制.
主要方法:
- 一项介入前后的研究,涉及HFpEF患者接受3个月的empagliflozin治疗.
- 微血管功能在血管活性刺激 (乙胆,胰岛素,酸) 的离子泳过程中使用激光光斑对比分析来评估.
- 主要结局:前臂微血管中的皮肤血管导电率 (CVC) 的变化;次要结局:生活质量 (EQ-5D-5L).
主要成果:
- 恩帕格利弗洛辛治疗导致血流对乙胆的反应降低 (p < 0.001).
- 相反,对胰岛素的血流反应显著改善 (p = 0.03).
- 对酸的反应保持不变,并且在微血管变化和生活质量之间没有发现相关性.
结论:
- 三个月的empagliflozin改变了HFpEF患者的外周微血管功能.
- 恩帕格利弗洛辛可以通过胰岛素特定途径改善微血管血流.
- 在HFpEF中,全身微血管功能障碍似乎可以通过empagliflozin进行修改,临床意义需要进一步研究.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
305
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
305
01:22Heart Failure Drugs: Diuretics
282
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
282
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:23Dipeptidyl Peptidase 4 Inhibitors
125
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
125
01:22Heart Failure Drugs: β-Blockers
260
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
260